These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 8752444

  • 1. [Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials].
    Ozawa K, Saida T.
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1501-3. PubMed ID: 8752444
    [Abstract] [Full Text] [Related]

  • 2. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 3. [Is immunosuppression a future therapeutic strategy for multiple sclerosis?].
    Edan G, Coustans M.
    Pathol Biol (Paris); 2000 Mar; 48(2):114-20. PubMed ID: 10815287
    [Abstract] [Full Text] [Related]

  • 4. Multiple sclerosis: use of MRI in evaluating new therapies.
    Miller DH.
    Semin Neurol; 1998 Mar; 18(3):317-25. PubMed ID: 9817536
    [Abstract] [Full Text] [Related]

  • 5. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
    Goodkin DE.
    West J Med; 1994 Sep; 161(3):292-8. PubMed ID: 7975569
    [Abstract] [Full Text] [Related]

  • 6. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.
    Neurology; 2009 Feb 24; 72(8):705-11. PubMed ID: 19073945
    [Abstract] [Full Text] [Related]

  • 7. The use of MRI as an outcome measure in clinical trials.
    Li DK, Li MJ, Traboulsee A, Zhao G, Riddehough A, Paty D.
    Adv Neurol; 2006 Feb 24; 98():203-26. PubMed ID: 16400836
    [Abstract] [Full Text] [Related]

  • 8. Early treatment trials with interferon beta in multiple sclerosis.
    Panitch HS.
    Mult Scler; 1995 Feb 24; 1 Suppl 1():S17-21. PubMed ID: 9345392
    [Abstract] [Full Text] [Related]

  • 9. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
    Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
    [Abstract] [Full Text] [Related]

  • 10. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 10; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 11. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
    Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
    Mult Scler; 2008 Apr 10; 14(3):370-82. PubMed ID: 18208877
    [Abstract] [Full Text] [Related]

  • 12. [Prognosis in multiple sclerosis].
    Kesselring J.
    Schweiz Med Wochenschr; 1997 Mar 22; 127(12):500-5. PubMed ID: 9148400
    [Abstract] [Full Text] [Related]

  • 13. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC.
    J Neurol Sci; 2004 Aug 15; 223(1):69-71. PubMed ID: 15261564
    [Abstract] [Full Text] [Related]

  • 14. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P.
    Expert Rev Neurother; 2004 May 15; 4(3):455-63. PubMed ID: 15853542
    [Abstract] [Full Text] [Related]

  • 15. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients.
    Lebrun C, Bensa C, Debouverie M, Wiertlevski S, Brassat D, de Seze J, Rumbach L, Pelletier J, Labauge P, Brochet B, Tourbah A, Clavelou P, Club Francophone de la Sclérose en Plaques.
    Arch Neurol; 2009 Jul 15; 66(7):841-6. PubMed ID: 19597085
    [Abstract] [Full Text] [Related]

  • 16. Multiple sclerosis: clinical presentation, diagnosis and treatment.
    Brod SA, Lindsey JW, Wolinsky JS.
    Am Fam Physician; 1996 Sep 15; 54(4):1301-6, 1309-11. PubMed ID: 8816574
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH.
    Curr Med Res Opin; 2007 Jun 15; 23(6):1199-208. PubMed ID: 17559719
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of progressive forms of multiple sclerosis].
    Edan G.
    Rev Neurol (Paris); 2001 Sep 15; 157(8-9 Pt 2):1008-13. PubMed ID: 11787331
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis].
    Cazzato G, Antonello RM, Zorzon M, Torre P, Zivadinov R, Moretti R, Bragadin LM, De Masi R, Nasuelli D.
    Recenti Prog Med; 1999 Oct 15; 90(10):538-44. PubMed ID: 10592740
    [Abstract] [Full Text] [Related]

  • 20. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.
    BMC Neurol; 2006 May 23; 6():19. PubMed ID: 16719908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.